BB's Stock Haven

[Drugdoctor]

VSGN - serious NASDAQ play at .49! Why buy now? Well, here is the reason. This company has a Phase III study on a heart failure treatment that JUST COMPLETED!

The stock was sold hard on results that didn't meet investor expectations, however, a whole category of patients were helped. Read this!


While the ACCLAIM study did not reach the primary endpoint of significantly reducing the risk of death and cardiovascular hospitalization in the total population, this endpoint was met for the subgroup of 692 patients with New York Heart Association (NYHA) Class II chronic HF (39.1% risk reduction, p(equal sign)0.0003). The Company is continuing data analysis, and complete results for the ACCLAIM study are scheduled to be presented at the World Congress of Cardiology 2006, being held from September 2-6 in Barcelona, Spain.


"While ACCLAIM was a neutral study based on the total patient population that included NYHA Class II, III and IV patients, a pre-specified analysis in the subgroup of nearly 700 patients with NYHA Class II heart failure showed a powerful and very encouraging result," said Dr. James Young, Chairman, Division of Medicine at the Cleveland Clinic Foundation and Chairman of the Steering Committee for the ACCLAIM trial. "Celacade's broad-spectrum anti- inflammatory effects may be more beneficial in those patients who have not advanced to late stage disease, but who are at risk for doing so. From a healthcare system perspective, a therapy that reduces the rate of hospitalization in this large and underserved patient population would be very valuable. The therapy was also very well tolerated by patients, and in my experience, was better tolerated than many drug therapies used in heart failure. I would like to thank the investigators, my fellow Steering Committee members, the Data and Safety Monitoring Board and the Central Endpoints Committee for their diligent efforts in carrying out this very important, necessary, and well-executed study."

Now read this:

stated David Elsley, President and CEO of Vasogen. "We are currently completing the analysis of the ACCLAIM data in preparation for releasing full study results at this venue and at the World Congress of Cardiology in Barcelona, Spain, both in September. Based on our ongoing review of the data, we also look forward to providing an update on our plans to advance the commercial development of Celacade during our second quarter conference call in mid-July."

Now - Look at this chart- RSI way oversold and with this NEWS coming in a short time, the gap to $1.82 to fill, and the encouraging results, with the need to get the stock back over $1 to save the Nasdaq listing..... You decide!


http://stockcharts.com/h-sc/ui?s=VSGN&p=D&b=5&g=0&id=p72219258820